Get started
Author

Luwei Han

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
2021 · Luwei Han, Xiaomeng Zhang, et al. · Frontiers in Pharmacology · 31
PDF
Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China
2021 · Zhiqiang Wang, Zhibo Zhang, et al. · Acta Pharmaceutica Sinica B · 28
PDF
C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma
2021 · Mei Yang, Yanhong Su, et al. · Biochemical Pharmacology · 20
Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma from a phase Ib/II study.
2025 · Zhi Peng, Hong Zhu, et al. · Journal of Clinical Oncology · 12
PDF
Effects of the ornidazole enantiomers on the central nervous system: Involvement of the GABAA receptor
2015 · Ting-Ting Wei, Ji-Hong Sun, et al. · Chemico-Biological Interactions · 10
Ailanthone disturbs cross-talk between cancer cells and tumor-associated macrophages via HIF1-α/LINC01956/FUS/β-catenin signaling pathway in glioblastoma
2024 · Xubin Deng, Qianbing Zhang, et al. · Cancer Cell International · 9
Second-line ASKB589 plus chemotherapy for advanced gastric or gastroesophageal cancers: Results from cohort 5 of a phase I/II study.
2025 · Miao Zhang, Jifang Gong, et al. · Journal of Clinical Oncology · 3
Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics
2023 · Sufeng Zhou, Bijun Sha, et al. · Xenobiotica · 2
Fractionated irradiation promotes radioresistance and decreases oxidative stress by increasing Nrf2 of ALDH-positive nasopharyngeal cancer stem cells
2024 · Gong Zhang, Guosheng Duan, et al. · Annals of Medicine and Surgery · 1
Safety and efficacy results from a first-in-human, phase 1/2 study of ASKG915, an anti-PD-1/pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors.
2026 · Jiajia Li, Jian Zhang, et al. · Journal of Clinical Oncology
PDF
Discovery and development of the preclinical candidate (SH-1092), a potent third generation EGFR inhibitor for the treatment of NSCLC
2026 · Kejun Liu, Feiwan Zou, et al. · Bioorganic Chemistry
616 Initial safety and efficacy results from a first in human, phase 1/2 study of ASKG915, an anti-PD-1/Pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors
2025 · Jian Zhang, Jiajia Li, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract CT118: Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors
2024 · Tingting Song, Caicun Zhou, et al. · Cancer Research
Works count: 13
Citation count: 116
H-index: 6
I10-index: 5
Year
Topic
Type